Limited evidence of pseudoprogression following immune checkpoint inhibitor (ICI) therapy in glioblastoma
Related Experiment Video
Updated: Jan 31, 2026

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
Published on: April 16, 2019
John Y Rhee1,2, Juan Pablo Ospina Botero1,3, Thomas Nelson4
1Center for Neuro-Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston.
Abstract:
"Pseudoprogression" following immune checkpoint inhibitors (ICI) in glioblastoma is often considered in case of radiographic progression. To better characterize the frequency of this phenomenon in glioblastoma, we reviewed the imaging response characteristics of a total of 55 patients treated with ICI in the setting of recurrent (n = 45) or newly diagnosed (n = 10) disease. There was no evidence of pseudoprogression related to ICI-monotherapy in the entire cohort.
Related Concept Videos
The Evidence for Evolution
The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
Limiting Reactant
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
The Number e as a Limit
What is the Immune System?

